Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that it will present data for zelicapavir, an oral, once-daily N-protein inhibitor aimed at treating respiratory syncytial virus (RSV), at IDWeek 2026. The event is scheduled for October 21-24, 2026, and will take place virtually as well as at the Walter E. Washington Convention Center in Washington, DC.